IDT Leadership

Ajay Gannerkote

President

Ajay has spent over 20 years in the healthcare space spanning Life Sciences, Diagnostics and Medical Devices, and has been with Danaher since January 2025. Ajay joined IDT as President from Siemens Healthineers, where he was the President of the global Ultrasound business covering both diagnostic and interventional businesses.

Prior to Siemens Healthineers, Ajay served in leadership positions at KKR, McKinsey, Federal-Mogul and Infosys Technologies. At KKR, Ajay led the portfolio operations group for the Healthcare sector covering over $40B of investments across multiple sectors. Ajay specifically led transformations at Panasonic Healthcare eventually leading to a successful IPO as well as transformations at AmSurg a large ASC network in the US. At McKinsey, as Partner, Ajay led the global medical products operations group covering devices, life sciences tools, diagnostics and pharma sectors serving clients globally in strategy, commercial, product development, manufacturing and supply chain functions. At Federal-Mogul, Ajay led plant operations and supply chain management for the sealing systems and Aftermarket businesses respectively.

Ajay has an MBA from University of Michigan, Ann Arbor and a bachelor’s degree in Electronics and Communication Engineering from University of Mysore, India.

Ross Allen

General Counsel

Ross was appointed as General Counsel of IDT in May 2022. With a strong background in both science and law, Ross brings a unique perspective to the legal department. He leads a team of strategic legal professionals with a focus on growth and innovation, while maintaining high standards of regulatory compliance.

With a passion for both science and law, Ross has built a successful career in the biotechnology and medical device industries. He started as a scientist and gained hands-on experience with IDT products before transitioning to a legal career as an intellectual property and complex commercial litigator. Over the years, Ross has expanded his practice to encompass general legal advising and compliance, holding various positions as regional general counsel, including a four-year assignment with Align Technology (Invisalign) in Singapore where he helped establish the company's footprint in Asia.

Before joining IDT, Ross served as the Assistant General Counsel for Cepheid where he led global strategic transactions, commercial support, and legal operations in support of the company's rapid growth during the COVID-19 pandemic. He also served as Vice Chair of Danaher’s LGBTQ+ Friends Associate Resource Group, offering support to LGBTQ+ colleagues and promoting allyship across the organization. Within IDT, Ross actively supports the company’s diversity, equity, and inclusion (DE+I) efforts.

Ross holds a Bachelor of Science in Microbiology/Chemistry and a Master of Science in Molecular Pathology from Texas Tech University Health Sciences Center. He earned his JD from Southern Methodist University Dedman School of Law.

Mark Behlke, MD, PhD

Chief Scientific Officer

Mark has been a part of IDT for more than two decades and was appointed Chief Scientific Officer in 2013.

Mark joined IDT as a Research & Development (R&D) consultant in 1995 and was named Vice President and head of R&D in 1996. Over 26 years at IDT, Mark directed research programs and new product development in the areas of DNA thermodynamics, gene synthesis, probe chemistry, qPCR, NGS, antisense, RNA interference, and CRISPR genome editing. In 2021, Mark stepped down as head of R&D and transitioned to a part-time role as scientific advisor for IDT and the Danaher Life Sciences group.

Mark is an internationally recognized expert in the field of nucleic acid technologies, an inventor of more than 70 issued US Patents, and an author on over 150 scientific papers.

Mark holds a Bachelor of Science degree in Biology from Massachusetts Institute of Technology. He was awarded MD and PhD degrees from the Washington University School of Medicine in St. Louis, after doing his doctoral dissertation in the field of Immunogenetics. Mark completed an Internal Medicine residency at Brigham & Women’s Hospital and an Endocrinology Fellowship at the Longwood/Harvard program. Mark was a Howard Hughes Postdoctoral Fellow in Human Genetics at the Whitehead Institute for Biomedical Research at MIT.

Norm Fuller

Vice President, Platform Development

Norm has been part of IDT for more than a decade and was appointed Vice President, Platform Development in 2014. He has spent his career within the Life Sciences and Biotech space.

Norm joined IDT in 2007 as a Process Engineer and over the years has progressively increased his responsibilities and impact on the Company. He brought the rigor associated with statistical analysis, experimental design, and problem-solving methodologies to IDT which have been instrumental in making many of the technology advancements related to IDT manufacturing technology over the past decade.

Before joining IDT, Norm worked for Motorola, Amersham Biosciences, and GE Healthcare developing manufacturing processes supporting the buildup of novel products in the biotechnology sector.

Norm holds a Bachelor of Science and a master’s degree in Chemical Engineering from Brigham Young University.

Mike Ashley

Vice President, Research & Development

Mike joined IDT in May 2023 as Sr. Director, Bioinformatics and since that time has taken on expanded responsibility for software and digital experience. In September 2024, he was appointed as Vice President, Research & Development and leads IDT's global R&D team.

Mike has extensive leadership experience from his more than 20 years at Beckman Coulter Life Sciences, where he led many large R&D teams. He was the Chief Engineer and Core Team leader for the Biomek i-Series liquid handlers, and went on to lead R&D for the Flow Cytometry business, encompassing RUO and IVD reagents and assays as well as analytical instrument development, spanning five R&D sites globally.

Mike has a PhD in Computer Science and brings deep knowledge of software and systems.

Abhijit Shah

Vice President, Digital Transformation

Abhijit Shah serves as Vice President, Digital Transformation at Integrated DNA Technologies (IDT). Abhijit brings deep experience in custom manufacturing environments and has led large_scale digital, eCommerce, and AI_driven transformation programs throughout his career.

Prior to joining IDT, he served as Vice President, Digital Solutions at Revvity, where he oversaw global business applications and ERP transformation. He previously held leadership roles at Siemens Healthineers as Divisional CIO and Head of Transformation for the Ultrasound Business Group, joining through the acquisition of Varian Medical Systems, where he spent eight years leading enterprise applications.

Abhijit holds a Bachelor of Engineering in Mechanical Engineering from the University of Pune.

Konstantin Fiedler

Vice President and General Manager, Gene Reading Business Unit

Konstantin is an experienced senior leader in the life-science space. He joined IDT as of September 2024 and leads IDT's Gene Reading Business Unit. He comes to IDT from Foundation Medicine, where he served for the last 6 years as COO and led a global cross-functional team responsible for providing scalable NGS processing of tissue and liquid cancer samples.

Prior to Foundation Medicine, he was head of Innovation and a member of the Global Executive Team of Linde Healthcare in Germany. Other prior experience includes leading Leica Biosystem’s Advanced Staining business; as well as leading a protein separation business, a protein analysis business and a cell analysis business – all three of which are now part of Cytiva. He has broad functional experience, leading Corporate Development, Product Innovation, Marketing, Client Services, Operations, Quality, and IT/software development functions.

Konstantin holds a Ph.D. in Physics from Universität Konstanz, Germany, and a Master of Science in Physics from Karl-Franzens Universität Graz, Austria.

Nichole Riek

VP of Global QARA

Nichole joined IDT as Vice President, Quality and Regulatory in August 2022 with extensive experience in both heavily regulated and research markets and demonstrated results in building effective processes and systems. Prior to joining IDT, Nichole spent six years with SCIEX, where she led as the Vice President of QA/RA, strategically directing the establishment, implementation, and maintenance of adherent QA/RA systems as well as building regulatory strategies for medical device launches in key markets.

Nichole also played a leading role in driving forward SCIEX’s D+I strategy—an initiative she is deeply passionate about—and helped the team deliver tremendous impact in 2022. Prior to joining SCIEX, Nichole managed the global regulatory affairs team at Boston Scientific’s Urology and Pelvic Health Division for 10 years.

Nichole holds a Bachelor of Science in Biomedical Engineering from Western New England College in Springfield, MA, U.S.A.

Sarah Smith

Vice President, Human Resources

Sarah joined IDT as Vice President, Human Resources (HR) in August 2023. In this role, Sarah is responsible for leading IDT’s HR and Communications functions. These efforts entail leading human resource service delivery to IDT associates in the areas of organizational design, HR policy and procedure, diversity and inclusion efforts, employee relations and engagement, culture, and talent development.

Sarah has held multiple roles of increasing responsibility since joining Danaher in May 2012. Most recently, Sarah led HR service delivery for the Danaher Corporate organization as Vice President, Human Resources responsible for providing strategic HR support to the Danaher Corporate leadership team. During her tenure as Vice President, Human Resources for Corporate, she led the HR workstreams for the Veralto separation. Prior to that, she led HR North America as well as several other HR Business Partner positions at ChemTreat.

Sarah graduated Magna Cum Laude with a bachelor’s degree in business administration from the University of Mary Washington.

Joshua Wu

General Manager, IDT China

Joshua joined SCIEX, part of Danaher, in 2014 as sales leader for the CE product line. He transferred to the SCIEX China L1 DBSL (Danaher Business System Leader) role in 2019 and led the full DBS capability build up with both internal and external partners to deliver sustainable business results. He transferred to Strategical Solutions Director of SCIEX China in Oct. 2021, where he built the SCIEX China localization and innovation capability from the bottom up. During his tenure, he led the development and execution of multiply China localization, open innovation, and strategical partnership initiatives, helping to build SCIEX into the biggest Life Sciences Innovations Group Operating Company in China.

Joshua received his bachelor’s degree in Bioengineering and MBA from Beijing Institute of Technology University. Prior to Danaher, Joshua acquired more than 10 years of experience in the Life Science industry, within roles such as a sales manager at Bio-Rad where he accumulated foundational genomic knowledge. Before that, he was with GE Lifesciences, which is Cytiva today, as sales manager for Whatman business.